Security
CERo Therapeutics Holdings Inc. Warrants · CEROW
CEROWNASDAQWarrantHistorical · closed Oct 30, 2025CIK 1870404Updated Oct 8, 2026
Name history
CERO THERAPEUTICS HOLDINGS, INC. · through Oct 7, 2026PHOENIX BIOTECH ACQUISITION CORP. · through Feb 14, 2024
Current security for this SEC filerCERO · OTC
CEROW price & chart
Historical security
This listing closed Oct 30, 2025. Live provider charts are shown only for current listings.
Current security: CERO
About the company
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering integrates key functional attributes of both innate and adaptive immunity within a single therapeutic construct, designed to engage the body’s immune repertoire for more comprehensive tumor targeting. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells toward tumor cells through both adaptive perforin/granzyme pathways and innate engulfment mechanisms, including targeting of the TIM-4 ligand. This employs phagocytic activity to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated targeting properties of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has initiated clinical trials for its lead product candidate, CER-1236, for hematologic malignancies.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 1.02, 2.03, 3.02, 9.01
424B3 filing
10-Q filing
SCHEDULE 13G/A - filed by Tibbs Isaiah regarding CERO THERAPEUTICS HOLDINGS, INC.
Show 5 more recent filings
424B3 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
424B3 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities
Items 1.01, 2.03, 3.02, 9.01
424B3 filing
Financials
FY 2025 · USDSource
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 3,911,394Source | 6,491,997Source | 1,899,971Source | 6,202,322Source | 7,370,765Source | 2,205,110Source | 7,991,414Source | 9,052,656Source | 3,641,134Source | 6,206,929Source | 8,560,610Source | 42,367,032Source |
| Property, Plant and Equipment, NetUSD | 313,452Source | 624,900Source | 125,947Source | 382,806Source | 738,755Source | 184,449Source | 452,227Source | 853,059Source | 246,148Source | 528,521Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,900,000Source | — | 862,756Source | 3,227,918Source | — | — | 5,100,000Source | — | — | — | 96,873Source | 475,870Source |
| Assets, CurrentUSD | 2,553,899Source | 3,714,483Source | 1,547,950Source | 4,246,566Source | 4,245,911Source | 1,574,398Source | 5,768,001Source | 5,501,205Source | 2,734,280Source | 3,714,041Source | — | 42,367,032Source |
| Prepaid Expense and Other Assets, CurrentUSD | 531,827Source | 334,279Source | 610,438Source | 443,892Source | 511,456Source | 716,909Source | 564,464Source | 746,045Source | 1,071,900Source | 274,749Source | 27,426Source | 225,188Source |
| Operating Lease, Right-of-Use AssetUSD | 869,538Source | 1,652,614Source | 226,074Source | 1,072,950Source | 1,836,099Source | 446,263Source | 1,271,186Source | 2,015,047Source | 660,706Source | 1,464,367Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 8,454,556Source | 10,194,422Source | 32,405,268Source | 7,836,223Source | 9,852,633Source | 11,463,865Source | 8,320,800Source | 13,031,753Source | 9,087,596Source | 8,101,492Source | 14,323,421Source | 39,898,341Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Additional Paid in CapitalUSD | 73,055,709Source | 66,363,448Source | 65,961,431Source | 71,311,399Source | 57,632,881Source | 80,288,145Source | 73,345,026Source | 53,994,723Source | 78,126,104Source | 67,142,046Source | — | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -86,297,494Source | -71,589,745Source | -97,752,859Source | -81,441,099Source | -67,361,778Source | -96,724,029Source | -76,023,784Source | -64,913,124Source | -90,838,115Source | -70,917,853Source | -14,199,669Source | — |
| Stockholders' Equity Attributable to ParentUSD | -4,543,162Source | -3,702,425Source | -30,505,297Source | -1,633,901Source | -2,481,868Source | -9,258,755Source | -329,386Source | -3,979,097Source | -5,446,462Source | -1,894,563Source | -14,199,122Source | -10,755,377Source |
| Liabilities and EquityUSD | 3,911,394Source | 6,491,997Source | 1,899,971Source | 6,202,322Source | 7,370,765Source | 2,205,110Source | 7,991,414Source | 9,052,656Source | 3,641,134Source | 6,206,929Source | 8,560,610Source | 42,367,032Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,454,556Source | 9,422,897Source | 32,405,268Source | 7,617,915Source | 8,779,323Source | 11,327,100Source | 7,859,220Source | 11,651,445Source | 9,087,596Source | 7,402,385Source | 5,173,421Source | 30,748,341Source |
| Operating Lease, Liability, CurrentUSD | 931,023Source | 931,023Source | 218,308Source | 934,310Source | 821,318Source | 461,580Source | 905,005Source | 794,893Source | 699,107Source | 876,392Source | — | — |
| Accounts Payable, CurrentUSD | 7,077,342Source | 6,667,073Source | 8,216,774Source | 6,213,045Source | 6,347,348Source | 7,686,681Source | 6,379,056Source | 7,059,695Source | 7,580,899Source | 4,507,318Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | — | 771,525Source | — | 218,308Source | 1,073,310Source | — | 461,580Source | 1,366,585Source | — | 699,107Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 340,691Source | 1,692,527Source | 485,009Source | 365,060Source | 1,157,483Source | 500,788Source | 469,659Source | 294,343Source | 363,811Source | 1,913,175Source | — | — |
| Deferred Revenue, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 9,150,000Source | — |
| Dividends Payable, CurrentUSD | — | — | 85,500Source | — | — | 85,500Source | — | — | 85,500Source | — | — | — |
| Deferred Compensation Equity | — | — | — | —Source | — | —Source | — | — | — | — | — | — |
| Long-term Debt | — | — | — | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 5,900,000Source | — | 19,900,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 2,800,000Source | — | -16,100,000Source | — | -1,523,604Source | -1,092,247Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | -7,944,740Source | 180,839,396Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 33,481,627Source | 139,353,878Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | -32,576,627Source | -138,703,878Source |
| Dividends paid | — | — | — | — | — | — | —Source | —Source | —Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | — | -42,044,971Source | 41,043,271Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 2,022,072Source | 3,380,204Source | 937,512Source | 3,302,674Source | 3,647,026Source | 857,489Source | — | 1,662,380Source | 3,327,060Source | 96,873Source | 42,141,844Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | 348,116Source | 20,000Source | 1,122,085Source | 183,328Source | 30,000Source | 1,617,455Source | 304,946Source | 1,096,056Source | 924,668Source | — | — |
| Dividends Payable, CurrentUSD | — | — | — | 85,500Source | — | — | 85,500Source | — | 85,500Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | 3,339,223Source | — | — |
| General and Administrative ExpenseUSD | — | 1,976,335Source | 2,628,028Source | 2,110,453Source | 1,969,828Source | 2,433,893Source | 2,507,383Source | 2,042,704Source | — | 8,985,351Source | 2,892,935Source | 2,841,391Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 94,819Source | 599,159Source |
| InterestExpenseNonoperatingUSD | — | — | -4,418Source | 690,044Source | — | 16,977Source | 166,286Source | — | — | -21,846Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 491,571Source | 2,836,864Source |
| Net Income (Loss) Attributable to ParentUSD | — | -4,856,395Source | -4,227,967Source | -1,028,830Source | -5,417,315Source | -2,448,654Source | -5,885,914Source | -5,105,931Source | -19,920,262Source | -7,732,212Source | -2,536,233Source | -667,736Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -11,506,223Source | -4,227,967Source | -29,455,454Source | -30,117,689Source | -2,448,654Source | -5,885,914Source | -5,454,158Source | — | -10,517,051Source | — | — |
| Nonoperating Income (Expense)USD | — | -493,816Source | 174,271Source | 2,817,636Source | -693,524Source | 2,699,583Source | -1,040,186Source | -155,400Source | — | 7,568,691Source | — | — |
| Operating ExpensesUSD | — | 4,362,579Source | 4,402,238Source | 3,846,466Source | 4,723,791Source | 5,148,237Source | 4,845,728Source | 4,950,531Source | — | 15,300,903Source | — | 2,905,441Source |
| Proceeds from Issuance of Common StockUSD | — | — | 1,700,000Source | — | — | — | — | — | — | — | — | 0Source |
| Depreciation | — | —Source | —Source | —Source | —Source | —Source | — | —Source | — | — | — | — |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Other Nonoperating Income (Expense) | — | —Source | —Source | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | -4,362,579Source | -4,402,238Source | -3,846,466Source | -4,723,791Source | -5,148,237Source | -4,845,728Source | -4,950,531Source | — | -15,300,903Source | -2,932,985Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -19,920,262Source | — | -2,441,414Source | -68,577Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | 94,819Source | 599,159Source |
| Net Income (Loss) Attributable to ParentUSD | — | -4,856,395Source | -4,227,967Source | -1,028,830Source | -5,417,315Source | -2,448,654Source | -5,885,914Source | -5,105,931Source | -19,920,262Source | -7,732,212Source | -2,536,233Source | -667,736Source |
| Earnings Per Share, BasicUSD per share | — | -9.1Source | -170.22Source | -0.7Source | -61.71Source | -302.32Source | -0.2Source | -31.82Source | — | -18.15Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | -9.1Source | -170.22Source | -0.7Source | -61.71Source | -302.32Source | -0.2Source | -31.82Source | — | -18.15Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 1,264,884Source | 24,838Source | 42,175,020Source | 488,076Source | 8,099Source | 28,755,073Source | 171,381Source | — | 579,432Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 1,264,884Source | 24,838Source | 42,175,020Source | 488,076Source | 8,099Source | 28,755,073Source | 171,381Source | — | 579,432Source | — | — |
| Interest Expense (non-operating)USD | — | — | -4,418Source | 690,044Source | — | 16,977Source | 166,286Source | — | — | -21,846Source | — | — |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 10.37Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | -94,819Source | 599,159Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | 3,339,223Source | — | — |
| General and Administrative ExpenseUSD | — | 1,976,335Source | 2,628,028Source | 2,110,453Source | 1,969,828Source | 2,433,893Source | 2,507,383Source | 2,042,704Source | — | 8,985,351Source | 2,892,935Source | 2,841,391Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -19,920,262Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | 491,571Source | 2,836,864Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -11,506,223Source | -4,227,967Source | -29,455,454Source | -30,117,689Source | -2,448,654Source | -5,885,914Source | -5,454,158Source | — | -10,517,051Source | — | — |
| Nonoperating Income (Expense)USD | — | -493,816Source | 174,271Source | 2,817,636Source | -693,524Source | 2,699,583Source | -1,040,186Source | -155,400Source | — | 7,568,691Source | — | — |
| Operating ExpensesUSD | — | 4,362,579Source | 4,402,238Source | 3,846,466Source | 4,723,791Source | 5,148,237Source | 4,845,728Source | 4,950,531Source | — | 15,300,903Source | — | 2,905,441Source |
| Other ExpensesUSD | — | — | 147Source | — | — | 630,775Source | — | 85,000Source | — | 672,378Source | 8,540,000Source | — |
| Other General and Administrative ExpenseUSD | — | 82,225Source | 300,000Source | 843,618Source | 129,507Source | — | 1,111,578Source | 231,644Source | 824,707Source | — | — | — |
| Research and Development ExpenseUSD | — | 2,386,244Source | 1,774,210Source | 1,736,013Source | 2,753,963Source | 2,714,344Source | 2,338,345Source | 2,907,827Source | — | 6,315,552Source | — | — |
| Other Nonoperating Income (Expense) | — | —Source | —Source | — | — | — | —Source | — | — | — | — | — |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Interest Income (Expense), Nonoperating, Net | — | —Source | —Source | — | —Source | —Source | — | —Source | — | — | — | — |
| Interest Income, Other | — | — | — | —Source | —Source | — | —Source | —Source | — | — | — | — |
| Other Income | — | — | — | — | — | —Source | — | — | — | — | — | — |
| Preferred Stock Dividends and Other Adjustments | — | — | — | — | —Source | — | — | —Source | — | — | — | — |
Filing attachments
ea030132301ex4-10.htm · 10-Q · 2026-08-14
Exhibit 4.10 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AME NDE D (T HE “1933 ACT”), OR ANY U.S. STATE. SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN …
Read attachment ↗ea029846301ex4-1.htm · 8-K · 2026-07-17
EX-4.1 2 ea029846301ex4-1.htm SECOND AMENDED AND RESTATED NOTE (JULY 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AME NDE D (T HE “1933 ACT”), OR ANY U.S. STATE. SECURITIES LAWS, AND,…
Read attachment ↗ea029602201ex4-1.htm · 8-K · 2026-06-26
EX-4.1 2 ea029602201ex4-1.htm AMENDED AND RESTATED NOTE (JUNE 2026) Exhibit 4.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AME NDE D (T HE “1933 ACT”), OR ANY U.S. STATE. SECURITIES LAWS, AND, UNLESS…
Read attachment ↗ea028527101ex4-5.htm · 10-K · 2026-04-15
Exhibit 4.5 DESCRIPTION OF SECURITIES The following summary of the material terms of the securities of CERo Therapeutics Holdings, Inc. (“we,” “our,” “us,” or the “Company”) is not intended to be a complete summary of the rights and preferences of such securities. You are encouraged to read the applicable provisions of Delaware law, the Second Amended and Restated Certificate of Incorporation, as amended from time to time (the “Certificate of Incorporation”), the Second Amended and Restated By…
Read attachment ↗ea027698401ex4-1_cero.htm · 8-K · 2026-02-13
Exhibit 4.1 NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT O F 1933, AS AME NDE D (THE “ 1933 ACT”), OR ANY U.S. STATE. SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE 1933 ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION…
Read attachment ↗ea027541201ex99-1_cero.htm · 8-K · 2026-02-04
Exhibit 99.1 CER - 1236 is a first - in - class chimeric antigen receptor T - cell (CAR - T) therapy designed to induce phagocytic target clearance through a TIM - 4 - based receptor ectodomain. TIM - 4 targets TIM - 4 - L, or phosphatidylserine, a structural phospholipid expressed on apoptotic and cancerous cells, especially acute myeloid leukemia, but absent on healthy cells. TIM - 4 binding to its ligand results in both cytotoxic T cell killing and phagocytosis of target cells. This non - ca…
Read attachment ↗